Literature DB >> 11334962

Development of an ELISA to measure soluble CD163 in biological fluids.

T H Sulahian1, K A Hintz, K Wardwell, P M Guyre.   

Abstract

CD163 is a monocyte/macrophage restricted transmembrane glycoprotein and a member of the scavenger receptor cysteine-rich (SRCR) family of proteins. SRCR proteins are typically associated with the immune system. The regulation of CD163 by cytokines and glucocorticoids suggests that it plays a role in inflammatory processes. While CD163 is expressed as a membrane-bound protein, it has been shown to be actively shed from the surface of monocytes in a protease-dependent fashion when cells are stimulated with a phorbol ester. To better elucidate the function and biological importance of CD163, we have developed a solid-phase sandwich enzyme linked immunosorbant assay (ELISA) for the detection of soluble CD163 in biological fluids. This assay has good repeatability both within and between runs (coefficients of variation (CVs) of 3.2% and 7.1% or better, respectively). While detection of CD163 was inhibited by ethylenediamine tetraacetic acid (EDTA), CD163 immunoreactivity was not altered by the addition of heparin or hemoglobin. This report details the development of this novel assay for soluble CD163 and provides the first evidence of CD163 immunoreactivity in normal plasma and serum samples.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11334962     DOI: 10.1016/s0022-1759(01)00328-3

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

1.  Serum levels of soluble CD163 in patients with systemic sclerosis.

Authors:  Wakana Nakayama; Masatoshi Jinnin; Katsunari Makino; Ikko Kajihara; Takamitsu Makino; Satoshi Fukushima; Yuji Inoue; Hironobu Ihn
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

2.  Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3.

Authors:  N Matsushita; M Kashiwagi; R Wait; R Nagayoshi; M Nakamura; T Matsuda; P Hogger; P M Guyre; H Nagase; T Matsuyama
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

3.  The intrathecal CD163-haptoglobin-hemoglobin scavenging system in subarachnoid hemorrhage.

Authors:  James Galea; Garth Cruickshank; Jessica L Teeling; Delphine Boche; Patrick Garland; V Hugh Perry; Ian Galea
Journal:  J Neurochem       Date:  2012-03-30       Impact factor: 5.372

4.  Soluble CD163: A novel biomarker for the susceptibility to sepsis in severe burn injuries.

Authors:  Andrzej Piatkowski; Gerrit Grieb; Rittuparna Das; Ahmet Bozkurt; Dietmar Ulrich; Norbert Pallua
Journal:  Indian J Plast Surg       Date:  2011-01

5.  Effect of bone marrow mesenchymal stem cell transplantation on acute hepatic failure in rats.

Authors:  Shufang Yuan; Tao Jiang; Rongjiong Zheng; Lihua Sun; Guiqiu Cao; Yuexin Zhang
Journal:  Exp Ther Med       Date:  2014-07-16       Impact factor: 2.447

6.  CD163 promotes hematoma absorption and improves neurological functions in patients with intracerebral hemorrhage.

Authors:  Wen-Jing Xie; Hong-Quan Yu; Yu Zhang; Qun Liu; Hong-Mei Meng
Journal:  Neural Regen Res       Date:  2016-07       Impact factor: 5.135

7.  Leucine-Rich Repeat Kinase 2 Influences Fate Decision of Human Monocytes Differentiated from Induced Pluripotent Stem Cells.

Authors:  Anna Speidel; Sandra Felk; Peter Reinhardt; Jared Sterneckert; Frank Gillardon
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

8.  The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma.

Authors:  Ling-Qun Kong; Xiao-Dong Zhu; Hua-Xiang Xu; Ju-Bo Zhang; Lu Lu; Wen-Quan Wang; Qiang-Bo Zhang; Wei-Zhong Wu; Lu Wang; Jia Fan; Zhao-You Tang; Hui-Chuan Sun
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

Review 9.  Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure.

Authors:  Marlene Christina Nielsen; Rasmus Hvidbjerg Gantzel; Joan Clària; Jonel Trebicka; Holger Jon Møller; Henning Grønbæk
Journal:  Cells       Date:  2020-05-09       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.